Skip to main content

Tafamidis Dosage

Medically reviewed by Drugs.com. Last updated on Sep 6, 2022.

Applies to the following strengths: meglumine 20 mg; 61 mg

Usual Adult Dose for Amyloidogenic Transthyretin Amyloidosis

Tafamidis meglumine (Vyndaqel): 80 mg orally once a day (Four 20 mg capsules/day)
OR
Tafamidis (Vyndamax): 61 mg orally once a day (One 61 mg capsule/day)

Comments:

  • Tafamidis and tafamidis meglumine products are not substitutable on a per mg basis.

Use: For the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended
Severe liver dysfunction: Use with caution

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Tafamidis and tafamidis meglumine are not interchangeable on a per mg basis.
  • Take orally once a day with or without food; the capsules should be swallowed whole, not crushed or chewed.

Missed Dose: If a dose is missed, take the dose as soon as remembered or skip the missed dose and take the next dose at the regularly scheduled time; do not double the dose

General:
  • For patients with wild type or hereditary transthyretin-mediated amyloidosis, there is an international disease registry called the Transthyretin Amyloidosis Outcome Survey (THAOS), designed to assess disease progression, genotype/phenotype relationships, and the impact of interventions, including this drug, on disease progression; participation is voluntary, and may involve long-term follow-up. For information regarding the registry, visit www.thaos.net.

Patient advice:
  • Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
  • Patients should be advised of the availability of the Transthyretin Amyloidosis Outcome Survey (THAOS) international voluntary registry designed to assess disease progression, genotype/phenotype relationships, and the impact of interventions.
  • Advise pregnant women and females of reproductive potential of the potential risk to a fetus and to inform of a known or suspected pregnancy; pregnancy should be reported to Pfizer reporting line at 1-800-438-1985.
  • Advise females not to breastfeed during treatment.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.